More recently, MDSC from ESCC patients were shown to secrete TGF-β, which in turn increased PD-1 expression on tumor-infiltrating CD8+ T cells and enhanced their resistance to PD-1/PD-L1 blockade. This evidence concerns the gene TGFB1 and neoplasm.